New Hybrid Capture method for comprehensive genome analysis

Since mid-2015, a new Hybrid-Capture based genetic analysis method is available within the framework of the network NGM. In one approach this method tests a very comprehensive panel of 83 oncogenes and can determine multiple genetic aberrations (mutations, deletions, amplifications, translocations) in one process. In this very comprehensive approach to the analysis of cancer genomes, numerous genes are detected that are of great importance for therapeutic decisions in other malignant tumors, including, for example, colorectal, gastric and esophageal cancer (see Gastrointestinal Cancer Group Cologne).

The Network Genomic Medicine will therefore ensure that within the framework of this diagnostics, new molecular biomarkers, which are of crucial importance for all therapies, known or still in clinical testing, are determined continuously.

Further information about the new Hybrid-Capture method will follow soon.

Last update: 29. February 2016 , 14:07

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.
Share This